on INVENTIVA (EPA:IVA)
Inventiva files its Universal Registration Document and its 2025 Annual Report
On April 8, 2026, the biopharmaceutical company Inventiva, listed on Euronext Paris and Nasdaq, announced the filing of its 2025 Universal Registration Document. This document, which includes the annual management and financial report, relates to the financial year ending December 31, 2025. It was submitted to the Autorité des Marchés Financiers (AMF) and its equivalent, Form 20-F, to the Securities and Exchange Commission (SEC) in the United States.
Based in Daix, France, Inventiva specializes in the development of oral therapies, particularly for treating metabolic steatohepatitis, or MASH. The filed documents are available on the company's website, as well as on those of the AMF and the SEC.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news